15 Juni 2015

EuropaBio and Smithers Rapra confirm agenda for 8th edition of EFIB

Themes to range from inspiring new business models, circular economy and creation of markets, issues of financing and funding in addition to the availability of feedstocks, and update on the status and outlook of biobased industries

EuropaBio and Smithers Rapra, in association with bio.be, are pleased to announce the agenda for the European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), which will build on the success of previous editions of this market-leading event. Taking place on 27-29 October at SQUARE Brussels Meeting Centre, EFIB 2015 will take advantage of the opportunity to increase engagement between policy makers and a broad range of stakeholders connected with the existing biobased value chain, and reach a new network of end users from a range of industries.

With themes ranging from inspiring new business models, circular economy and the creation of markets, to addressing the issues of ensuring financing and funding is available for commercialisation, in addition to the availability of feedstocks, this year’s EFIB agenda will provide a comprehensive update on the status and outlook of biobased industries

Featuring CEOs of key players who have recently announced significant investments in Europe into biorefineries and industrial biotechnologies; Global Bioenergies, Corbion, Metsa Fibre Ltd and Novamont will provide their perspectives on the state of business in Europe, from developing new and novel partnerships along the value chain, to ensuring that capital investment is made available.

Joanna Dupont-Inglis, Industrial Biotechnology Director at EuropaBio comments that there are many reasons for optimism in 2015. The last twelve months have seen several key supports to biobased development put in place, including the launch of the European Bioeconomy Alliance, the first calls for flagship projects as part of the Public Private Partnership for Biobased Industries and the first conclusions of the Bioeconomy Panel. Momentum continues to build around the topic of biobased industries and Industrial Biotechnology is increasingly seen as a priority ‘Key Enabler’ of a more competitive and resource efficient circular bioeconomy.

In parallel, Europe continues to see an increasingly high number of consumer brands, from automotive companies to sportswear, homecare, cosmetics and toy manufacturers, embracing the potential of new biobased materials. Reflecting this growing interest, companies such as Jaguar Landrover, FrieslandCampina and baby product manufacturer Bioserie will share their insights with the EFIB audience on the potential for higher use of biobased materials in the future.

Fast-moving consumer goods companies have also taken steps to embrace the circular economy and this hot topic will be addressed in our opening plenary, including expert insights from the Ellen MacArthur Foundation and Accenture. In addition to embracing circular business models and demonstrating the opportunities for the bioeconomy, these two companies will address the most pressing challenges that Europe needs to overcome in order to realise its potential.

While Industrial Biotechnology is currently estimated to be worth €28 billion in the EU, projections show that the EU market for IB products could develop to €40 billion by 2020 and up to €50 billion in 2050 with significant potential to become the dominant technology of Europe’s future chemicals industry.

The innovation tracks will ensure that crucial advancements in these technologies, processes and biomaterials are also given the chance to be showcased, with large players such as Stora Enso, Plaxica and Novasep demonstrating their recent work in advancing industrial biotechnology across various end use sectors.  Plus, SMEs have been given their own focus session, with AVA Biochem, GFBiochemicals, Biorem Engineering and more joining the agenda with new insights into platform chemicals, synthetic biology and sustainable chemistry solutions on the way to commercialisation.

EFIB 2015 will bring the worlds of policy and business together to discuss how to boost investment, innovation and value chain development to capture the potential of white biotechnology in Europe.

This is your chance to join 700 industry professionals in the heart of Europe for unparalleled networking and insights into industrial biotech to help grow your business and be part of the transition towards a European bioeconomy.

Book your place at this leading event now.

Source: EFIB, press release, 2015-06-08.

Supplier

Share on Twitter+1Share on FacebookShare on XingShare on LinkedInShare via email